Mismatch negativity in aging and in Alzheimer's and Parkinson's diseases

被引:121
|
作者
Pekkonen, E
机构
[1] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, BioMag Lab, Med Engn Ctr, Helsinki, Finland
[3] Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, SF-00100 Helsinki, Finland
关键词
event-related potential (ERP); mismatch negativity (MMN); memory trace decay; Alzheimer's disease; Parkinson's disease; aging; magnetoencephalography (MEG);
D O I
10.1159/000013883
中图分类号
R36 [病理学]; R76 [耳鼻咽喉科学];
学科分类号
100104 ; 100213 ;
摘要
Mismatch negativity (MMN) is an auditory event-related potential (ERP) that reflects automatic stimulus discrimination in the human auditory system. By varying the interstimulus intervals (ISIs), the MMN can be used as an index of auditory sensory memory. This paper focuses on MMN findings in aging and in Alzheimer's (AD) and Parkinson's diseases (PD). The accumulated data suggest that MMN to duration deviance, unlike MMN to frequency deviance, is reduced in amplitude in aging at short ISIs. The attenuated MMN to frequency deviance observed at long ISIs in elderly subjects seems to be caused by age-related memory trace decay. Existing results suggest that automatic discrimination for the frequency change is not affected in the early phase of AD, whereas the memory trace seems to decay faster in AD patients. The present findings on PD are not as conclusive, although they tentatively suggest deteriorated automatic change detection. The MMN appears to offer an objective tool for studying auditory processing and memory trace decay in different neurological disorders. Copyright (C) 2000 S. Karger AG, Basel.
引用
收藏
页码:216 / 224
页数:9
相关论文
共 50 条
  • [31] Molecular pathology links Alzheimer's and Parkinson's diseases
    Oransky, I
    LANCET NEUROLOGY, 2003, 2 (06): : 328 - 328
  • [33] Facial emotion expressivity in Parkinson's and Alzheimer's diseases
    Cannavacciuolo, A.
    Guerra, A.
    Colella, D.
    Salzillo, M.
    De Biase, A.
    Paparella, G.
    Canevelli, M.
    Bruno, G.
    Berardelli, A.
    Bologna, M.
    MOVEMENT DISORDERS, 2022, 37 : S650 - S651
  • [34] Modeling the neuroimmune system in Alzheimer’s and Parkinson’s diseases
    Wendy Balestri
    Ruchi Sharma
    Victor A. da Silva
    Bianca C. Bobotis
    Annabel J. Curle
    Vandana Kothakota
    Farnoosh Kalantarnia
    Maria V. Hangad
    Mina Hoorfar
    Joanne L. Jones
    Marie-Ève Tremblay
    Jehan J. El-Jawhari
    Stephanie M. Willerth
    Yvonne Reinwald
    Journal of Neuroinflammation, 21
  • [35] Pattern of brain destruction in Parkinson's and Alzheimer's diseases
    Braak, H
    Braak, E
    Yilmazer, D
    deVos, RAI
    Jansen, ENH
    Bohl, J
    JOURNAL OF NEURAL TRANSMISSION, 1996, 103 (04) : 455 - 490
  • [36] Modeling the neuroimmune system in Alzheimer's and Parkinson's diseases
    Balestri, Wendy
    Sharma, Ruchi
    da Silva, Victor A.
    Bobotis, Bianca C.
    Curle, Annabel J.
    Kothakota, Vandana
    Kalantarnia, Farnoosh
    Hangad, Maria V.
    Hoorfar, Mina
    Jones, Joanne L.
    Tremblay, Marie-Eve
    El-Jawhari, Jehan J.
    Willerth, Stephanie M.
    Reinwald, Yvonne
    JOURNAL OF NEUROINFLAMMATION, 2024, 21 (01)
  • [37] Pet Evaluation of Drugs in Alzheimer’s and Parkinson’s Diseases
    Karl Herholz
    Drug information journal : DIJ / Drug Information Association, 1997, 31 (3): : 1035 - 1044
  • [38] Common and Trace Metals in Alzheimer's and Parkinson's Diseases
    Doroszkiewicz, Julia
    Farhan, Jakub Ali
    Mroczko, Jan
    Winkel, Izabela
    Perkowski, Maciej
    Mroczko, Barbara
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (21)
  • [39] Microglia modulate neurodegeneration in Alzheimer's and Parkinson's diseases
    Bartels, Tim
    De Schepper, Sebastiaan
    Hong, Soyon
    SCIENCE, 2020, 370 (6512) : 66 - +
  • [40] Pfizer abandons research into Alzheimer's and Parkinson's diseases
    Hawkes, Nigel
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 360